ASH 2021 | Pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, shares the findings of a retrospective head-to-head comparison of pacritinib versus ruxolitinib in ruxolitinib-naïve patients with myelofibrosis and moderate-severe thrombocytopenia. Study participants were enrolled in the randomized Phase 3 PERSIST-2 study (NCT02055781) which compared the efficacy of pacritinib to best available therapy – ruxolitinib in 45% of cases- on spleen volume reduction (SVR) and modified total symptom score (TSS) responses. The results showed that patients in the pacritinib arm were able to maintain full doses over time, but they median daily dose of ruxolitinib dropped over the 24 weeks. Pacritinib produced greater rates of SVR and TSS response compared to ruxolitinib. Both agents had a similar safety profile. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
